Wolf Group Capital Advisors United Therapeutics Corp Transaction History

Wolf Group Capital Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Oct 23, 2018	SELL	$113.81 - $129.46 $256,072 - $291,285	-2,250 Closed	0 $0
Q2 2018 Jul 12, 2018	SELL	$101.14 - $118.31 $158,789 - $185,746	-1,570 Reduced 41.1%	2,250 $255,000
Q1 2018 Apr 25, 2018	SELL	$107.21 - $151.94 $658,269 - $932,911	-6,140 Reduced 61.65%	3,820 $429,000
Q4 2017 Feb 12, 2018	SELL	$118.58 - $151.28 $276,409 - $352,633	-2,331 Reduced 18.97%	9,960 $1.47 Million
Q3 2017 Oct 23, 2017	SELL	$114.6 - $136.81 $184,047 - $219,716	-1,606 Reduced 11.56%	12,291 $1.47 Million
Q2 2017 Aug 09, 2017	BUY	N/A	13,897	13,897 $1.8 Million

673

42.2M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.6B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Wolf Group Capital Advisors, based on Form 13F filings with the SEC.

Stay updated on Wolf Group Capital Advisors with notifications on news.